Financial results for the period ended Jun 30, 2026
As filed · Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
What happened
FactEmcure Pharmaceuticals Limited's Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026, during a meeting on August 06, 2026. The results, along with the Limited Review Reports from the statutory auditors, have been enclosed in the filing. Additionally, Mr. Berjis Desai, the Chairman and Non-executive, Non-Independent Director, will retire by rotation at the upcoming Annual General Meeting and has chosen not to seek re-appointment.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Order Book
WithdrawnRevenue from operations grew 22.8% to INR 2,580 crore, reflecting strong execution across both domestic and international businesses.
The order book across the different countries should also go up in line with the supplies.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- I believe that going forward, whether it is Q2, Q3, Q4, you will see the northward movements as far as the Ind (management committed by Q4 FY27)
- I would like to reiterate my confidence in Emcure to deliver low to mid-teen revenue growth in FY27. (management committed by FY27)
Evidence
- Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%